Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported a confirmed partial response in its ongoing Phase 1 clinical trial evaluating APR-1051, a WEE1 kinase inhibitor, in patients with biomarker-defined …
Aprea Reports Partial Response in APR-1051 Cancer Trial Read More DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) reported its fourth-quarter and full-year 2025 financial results and said early clinical data from its ongoing Phase 1 trial of APR-1051 showed …
Aprea Reports 2025 Results, Early Data for APR-1051 Trial Read More DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial showing a second unconfirmed partial response in a patient with advanced …
Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial Read More DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) said its president and chief executive officer, Oren Gilad, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences …
Aprea to Present at Oppenheimer Healthcare Conference Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. has appointed veteran physician-scientist Eugene (Gene) Kennedy, MD, as chief medical advisor, strengthening its leadership team as the biotechnology company advances a promising new …
Aprea Taps Veteran Oncologist as Clinical Momentum Builds for Lead Cancer Drug Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study of its experimental cancer drug APR-1051, an early signal the company …
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) told shareholders it is entering 2026 with advancing cancer programs, improving clinical signals, and a cash runway that management says extends into …
Aprea Signals 2026 Inflection as Cancer Trials Advance and Cash Extends Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported third-quarter 2025 financial results and highlighted steady progress across its two clinical-stage DNA damage response (DDR) programs, citing emerging signs of …
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced encouraging early clinical data from its ongoing Phase 1 ACESOT-1051 trial evaluating APR-1051, a first-in-class WEE1 kinase inhibitor, in patients with …
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that new data from its ongoing oncology programs will be featured in two poster presentations at the 2025 EORTC-NCI-AACR International Conference …
Aprea Therapeutics to Present New Data on APR-1051 and ATRN-119 at EORTC-NCI-AACR Conference Read More